GLP-1 drug for bone health in older women with diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests whether a diabetes medication called a GLP-1 receptor agonist can help improve bone and muscle health in older women with type 2 diabetes who are at risk for osteoporosis. It aims to see if the drug can strengthen bones and prevent falls.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 65 or older and have gone through menopause.
- You have type 2 diabetes and your blood sugar (A1c) is above 7%.
- Your body mass index (BMI) is between 27 and 40.
- You do not have osteoporosis (brittle bones) based on a recent bone scan.
- You are willing to follow study procedures, including some fasting visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a weekly injection (semaglutide) combined with an exercise program can help reduce fat stored in the heart and muscles in people with type 2 diabetes. It may improve how well your body handles sugar and lowers your risk for heart problems.
This study tests whether the diabetes medication semaglutide (which helps lower blood sugar) can also help protect your bones. It is for people with type 2 diabetes who have low bone density or a history of easy fractures, but not severe osteoporosis.
This trial tests whether a GLP-1 agonist (a type of diabetes medicine that also helps with weight loss) is safe and effective for people with spinal cord injury and type 2 diabetes who are not on other glucose-lowering drugs.
This trial tests whether cagrilintide, a medicine similar to a natural hormone called amylin, can affect bone health. It is for postmenopausal women with obesity who do not have bone disease or other conditions affecting bone metabolism.
This trial looks at how GLP-1 receptor agonist medications (like liraglutide or semaglutide) affect bone health in adolescents and young adults with obesity. It aims to understand if these weight loss drugs have any impact on bone density and metabolism.
This trial tests whether a lifestyle program (diet and exercise) can help prevent muscle loss in people 65 and older with type 2 diabetes and obesity who are taking semaglutide. It may help you keep your strength and independence while losing weight.
Hear when a new Diabetes Mellitus, Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.